• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Emergent BioSolutions Inc. - Product Pipeline Review - 2012 Product Image

Emergent BioSolutions Inc. - Product Pipeline Review - 2012

  • ID: 2135998
  • May 2012
  • 126 pages
  • Global Markets Direct

Emergent BioSolutions Inc. – Product Pipeline Review – 2012

Summary

Global Market Direct’s pharmaceuticals report, “Emergent BioSolutions Inc. - Product Pipeline Review - 2012” provides data on the Emergent BioSolutions Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Emergent BioSolutions Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Emergent BioSolutions Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Emergent BioSolutions Inc. - Brief Emergent BioSolutions Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Emergent BioSolutions Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current READ MORE >



List of Tables
List of Figures
Emergent BioSolutions Inc. Snapshot
Emergent BioSolutions Inc. Overview
Key Information
Key Facts
Emergent BioSolutions Inc. – Research and Development Overview
Key Therapeutic Areas
Emergent BioSolutions Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Emergent BioSolutions Inc. – Pipeline Products Glance
Emergent BioSolutions Inc. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Emergent BioSolutions Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Emergent BioSolutions Inc. – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Emergent BioSolutions Inc. – Drug Profiles
A2M1
Product Description
Mechanism of Action
R&D Progress
AH65
Product Description
Mechanism of Action
R&D Progress
Anthrivig
Product Description
Mechanism of Action
R&D Progress
Anti-CD19 X Anti-CD-3
Product Description
Mechanism of Action
R&D Progress
Anti-CD86 X Mono-IL-10
Product Description
Mechanism of Action
R&D Progress
Anti-HER2 X Anti-CD3
Product Description
Mechanism of Action
R&D Progress
Anti-PSMA X Anti-CD-3
Product Description
Mechanism of Action
R&D Progress
Anti-RON X Anti-CD3
Product Description
Mechanism of Action
R&D Progress
CTLA-4 X mono-IL-10
Product Description
Mechanism of Action
R&D Progress
ES301
Product Description
Mechanism of Action
R&D Progress
MVA85A
Product Description
Mechanism of Action
R&D Progress
NuThrax
Product Description
Mechanism of Action
R&D Progress
PreviThrax
Product Description
Mechanism of Action
R&D Progress
Thravixa
Product Description
Mechanism of Action
R&D Progress
TNFR x A2
Product Description
Mechanism of Action
R&D Progress
TNFR x TWEAKR
Product Description
Mechanism of Action
R&D Progress
TRU-016
Product Description
Mechanism of Action
R&D Progress
TRU-016 + Bendamustine
Product Description
Mechanism of Action
R&D Progress
Zanolimumab
Product Description
Mechanism of Action
R&D Progress
Emergent BioSolutions Inc. – Pipeline Analysis
Emergent BioSolutions Inc. – Pipeline Products by Therapeutic Class
Emergent BioSolutions Inc. – Pipeline Products By Target
Emergent BioSolutions Inc. – Pipeline Products by Route of Administration
Emergent BioSolutions Inc. – Pipeline Products By Mechanism of Action
Emergent BioSolutions Inc. – Recent Pipeline Updates
Emergent BioSolutions Inc. - Dormant Projects
Emergent BioSolutions Inc. – Company Statement
Emergent BioSolutions Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Emergent BioSolutions Inc., Recent Developments
Emergent BioSolutions Inc.- Press Release
Mar 22, 2012: Emergent BioSolutions Receives NIAID Grant To Support Tuberculosis Vaccine Candidate
Dec 07, 2009: HHS Cancels RFP for rPA Procurement and Modifies Their Approach in Favor of BAA for Development of rPA Vaccines
Nov 12, 2009: Trubion Announces Acceptance Of Two Presentations On Its TRU-016 Product Candidate At The 2009 ASH Annual Meeting
Nov 11, 2009: Trubion Announces Acceptance Of Two Presentations On Its TRU-016 Product Candidate At The 2009 ASH Annual Meeting
Sep 30, 2009: NIAID To Fund Development Of Emergent BioSolutions' Advanced Anthrax Vaccine Candidate
Jun 11, 2009: Emergent BioSolutions Meets With FDA To Review Regulatory Strategy For Recombinant Anthrax Vaccine
Jun 10, 2009: Emergent BioSolutions Receives FDA Approval Extending Shelf Life of BioThrax (Anthrax Vaccine Adsorbed) to 4 Years
Jun 01, 2009: Trubion Announces Positive Data From A Phase I / II Study Of TRU-016 For The Treatment Of Chronic Lymphocytic Leukemia (CLL)
May 14, 2009: Trubion Announces Acceptance Of Three Presentations On Its TRU-016 Product Candidate At The 2009 Asco Annual Meeting
May 13, 2009: Emergent Submits To FDA Development Plan For Recombinant Anthrax Vaccine
Apr 22, 2009: New TB Vaccine Candidate Enters Phase IIb Proof-of-Concept Trial In South Africa
Apr 22, 2009: New TB Vaccine Candidate Enters Phase IIb Proof-of-Concept Trial in South Africa
Mar 17, 2009: Emergent BioSolutions Announces Commencement Of Phase I/II Clinical Trial Of Anthrax Immune Globulin For Treating Anthrax Disease
Feb 12, 2009: Emergent BioSolutions Announces That BioThrax (Anthrax Vaccine Adsorbed) Receives Market Authorization in India
Financial Deals Landscape
Emergent BioSolutions Inc., Deals Summary
Emergent BioSolutions Inc., Pharmaceuticals & Healthcare, Deal Details
Asset Transactions
Emergent BioSolutions Acquires Rights Of Zanolimumab From TenX Biopharma
Emergent BioSolutions Acquires Manufacturing Facility From MdBio Foundation
Emergent BioSolutions Acquires A Lab Facility In Gaithersburg
Emergent BioSolutions Acquires FluBlok And Related Technology Assets From Protein Sciences
Emergent BioSolutions Acquires Assets And Related Technology Of Anthrax Vaccine Drug From VaxGen
AVANIR Pharma And Xenerex Sell Product Portfolio To Emergent BioSolutions
Venture Financing
Trubion Pharma Secures $32 Million In Series B Financing
Partnerships
Temasek Life Sciences Forms Joint Venture With Emergent BioSolutions
Facet Biotech Enters Into Co-Development Agreement With Trubion Pharma
Trubion Extends Its Co-Development Agreement With Wyeth Pharma
Emergent BioSolutions Enters Into Co-Marketing Agreement With Biological E
Emergent BioSolutions Forms Joint Venture With The University of Oxford
Trubion Pharma Extends Research Agreement With Wyeth Pharma
Emergent Biosolutions Amends Co-Marketing Agreement With Intergen
Emergent BioSolutions Forms Joint Venture With Ninebio
Trubion Expands Research Agreement With Dyax
Dyax Enters Into Agreement With Trubion Pharma
Wyeth Enters Into An Agreement With Trubion Pharma
Encorium Group Enters Into Co-Development Agreement With Emergent BioSolutions
Emergent BioSolutions Partners With Health Protection Agency
Licensing Agreements
Emergent BioSolutions Amends Licensing Agreement With Pfizer
Oxford BioMedica Enters Into Licensing Agreement With Emergent Product Development Germany
Emergent BioSolutions Enters Into Licensing Agreement With Pfizer
Xenerex Biosciences Enters Into Licensing Agreement With Emergent Biosolutions
Emergent BioSolutions Enters Into License Agreement With Coley Pharma
Emergent BioSolutions Enters Into Licensing Agreement With Sanofi Pasteur
Equity Offering
Emergent Biosolutions Completes IPO Of $62.5 Million
Trubion Pharma Completes IPO Of $60 Million
Acquisition
Emergent BioSolutions Completes The Acquisition Of Trubion Pharma
Emergent BioSolutions Acquires Vivacs
Emergent BioSolutions Acquires Microscience
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Emergent BioSolutions Inc., Key Information
Emergent BioSolutions Inc., Key Facts
Emergent BioSolutions Inc. – Pipeline by Indication, 2012
Emergent BioSolutions Inc. – Pipeline by Stage of Development, 2012
Emergent BioSolutions Inc. – Monotherapy Products in Pipeline, 2012
Emergent BioSolutions Inc. – Combination Treatment Modalities in Pipeline, 2012
Emergent BioSolutions Inc. – Phase III, 2012
Emergent BioSolutions Inc. – Phase II, 2012
Emergent BioSolutions Inc. – Phase I, 2012
Emergent BioSolutions Inc. – Pre-Clinical, 2012
Emergent BioSolutions Inc. – Pipeline By Therapeutic Class, 2012
Emergent BioSolutions Inc. - Pipeline By Target, 2012
Emergent BioSolutions Inc. – Pipeline By Route of Administration, 2012
Emergent BioSolutions Inc. – Pipeline Products By Mechanism of Action, 2012
Emergent BioSolutions Inc. – Recent Pipeline Updates, 2012
Emergent BioSolutions Inc. - Dormant Developmental Projects,2012
Emergent BioSolutions Inc., Other Locations
Emergent BioSolutions Inc., Subsidiaries
Emergent BioSolutions Inc., Deals Summary
Emergent BioSolutions Acquires Rights Of Zanolimumab From TenX Biopharma
Emergent BioSolutions Acquires Manufacturing Facility From MdBio Foundation
Emergent BioSolutions Acquires A Lab Facility In Gaithersburg
Emergent BioSolutions Acquires FluBlok And Related Technology Assets From Protein Sciences
Emergent BioSolutions Acquires Assets And Related Technology Of Anthrax Vaccine Drug From VaxGen
AVANIR Pharma And Xenerex Sell Product Portfolio To Emergent BioSolutions
Trubion Pharma Secures $32 Million In Series B Financing
Temasek Life Sciences Forms Joint Venture With Emergent BioSolutions
Facet Biotech Enters Into Co-Development Agreement With Trubion Pharma
Trubion Extends Its Co-Development Agreement With Wyeth Pharma
Emergent BioSolutions Enters Into Co-Marketing Agreement With Biological E
Emergent BioSolutions Forms Joint Venture With The University of Oxford
Trubion Pharma Extends Research Agreement With Wyeth Pharma
Emergent Biosolutions Amends Co-Marketing Agreement With Intergen
Emergent BioSolutions Forms Joint Venture With Ninebio
Trubion Expands Research Agreement With Dyax
Dyax Enters Into Agreement With Trubion Pharma
Wyeth Enters Into An Agreement With Trubion Pharma
Encorium Group Enters Into Co-Development Agreement With Emergent BioSolutions
Emergent BioSolutions Partners With Health Protection Agency
Emergent BioSolutions Amends Licensing Agreement With Pfizer
Oxford BioMedica Enters Into Licensing Agreement With Emergent Product Development Germany
Emergent BioSolutions Enters Into Licensing Agreement With Pfizer
Xenerex Biosciences Enters Into Licensing Agreement With Emergent Biosolutions
Emergent BioSolutions Enters Into License Agreement With Coley Pharma
Emergent BioSolutions Enters Into Licensing Agreement With Sanofi Pasteur
Emergent Biosolutions Completes IPO Of $62.5 Million
Trubion Pharma Completes IPO Of $60 Million
Emergent BioSolutions Completes The Acquisition Of Trubion Pharma
Emergent BioSolutions Acquires Vivacs
Emergent BioSolutions Acquires Microscience

List of Figures
Emergent BioSolutions Inc. – Pipeline by Indication, 2012
Emergent BioSolutions Inc. – Pipeline by Stage of Development, 2012
Emergent BioSolutions Inc. – Monotherapy Products in Pipeline, 2012
Emergent BioSolutions Inc. – Combination Treatment Modalities in Pipeline, 2012
Emergent BioSolutions Inc. – Pipeline By Therapeutic Class, 2012
Emergent BioSolutions Inc. - Pipeline By Target, 2012
Emergent BioSolutions Inc. – Pipeline By Route of Administration, 2012
Emergent BioSolutions Inc. - Pipeline Products By Mechanism of Action, 2012

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos